论文部分内容阅读
冠心病、心肌梗死、高血压病、心肌病、心瓣膜病等心血管疾病的最终结局都是心力衰竭,其共同特点是有完整舒缩功能的心肌细胞数量相对和绝对减少,受损心肌由纤维组织瘢痕修复[1],患者对于常规的药物治疗反应性极差,心脏移植虽能代替受损心脏,但供体难以选择,费用高,临床难以推广。如果能够在体外培育出大量可以转化为心肌细胞的干细胞,
The final outcome of cardiovascular diseases such as coronary heart disease, myocardial infarction, hypertension, cardiomyopathy and valvular heart disease are all heart failure, and their common feature is the relative and absolute decrease in the number of cardiomyocytes with intact and contractile function. The impaired myocardium consists of Fibrous tissue scar repair [1], patients with poor responsiveness to conventional drug therapy, heart transplantation can replace the damaged heart, but difficult to choose the donor, the high cost of clinical difficult to promote. If we can in vitro to cultivate a large number of stem cells can be transformed into cardiomyocytes,